G Brucato1, M D Masucci1, L Y Arndt1, S Ben-David1, T Colibazzi1, C M Corcoran1, A H Crumbley2, F M Crump1, K E Gill3, D Kimhy1, A Lister1, S A Schobel4, L H Yang5, J A Lieberman1, R R Girgis1. 1. The Center of Prevention and Evaluation,New York State Psychiatric Institute,Columbia University Medical Center,New York, NY,USA. 2. City University of New York,New York, NY,USA. 3. Department of Psychology,The Catholic University of America,Washington, DC,USA. 4. F. Hoffman-LaRoche A.G.,Basel,Switzerland. 5. Department of Social and Behavioral Sciences,College of Global Public Health, New York University,New York, NY,USA.
Abstract
BACKGROUND: DSM-5 proposes an Attenuated Psychosis Syndrome (APS) for further investigation, based upon the Attenuated Positive Symptom Syndrome (APSS) in the Structured Interview for Psychosis-Risk Syndromes (SIPS). SIPS Unusual Thought Content, Disorganized Communication and Total Disorganization scores predicted progression to psychosis in a 2015 NAPLS-2 Consortium report. We sought to independently replicate this in a large single-site high-risk cohort, and identify baseline demographic and clinical predictors beyond current APS/APSS criteria. METHOD: We prospectively studied 200 participants meeting criteria for both the SIPS APSS and DSM-5 APS. SIPS scores, demographics, family history of psychosis, DSM Axis-I diagnoses, schizotypy, and social and role functioning were assessed at baseline, with follow-up every 3 months for 2 years. RESULTS: The conversion rate was 30% (n = 60), or 37.7% excluding participants who were followed under 2 years. This rate was stable across time. Conversion time averaged 7.97 months for 60% who developed schizophrenia and 15.68 for other psychoses. Mean conversion age was 20.3 for males and 23.5 for females. Attenuated odd ideas and thought disorder appear to be the positive symptoms which best predict psychosis in a logistic regression. Total negative symptom score, Asian/Pacific Islander and Black/African-American race were also predictive. As no Axis-I diagnosis or schizotypy predicted conversion, the APS is supported as a distinct syndrome. In addition, cannabis use disorder did not increase risk of conversion to psychosis. CONCLUSIONS: NAPLS SIPS findings were replicated while controlling for clinical and demographic factors, strongly supporting the validity of the SIPS APSS and DSM-5 APS diagnosis.
BACKGROUND: DSM-5 proposes an Attenuated Psychosis Syndrome (APS) for further investigation, based upon the Attenuated Positive Symptom Syndrome (APSS) in the Structured Interview for Psychosis-Risk Syndromes (SIPS). SIPS Unusual Thought Content, Disorganized Communication and Total Disorganization scores predicted progression to psychosis in a 2015 NAPLS-2 Consortium report. We sought to independently replicate this in a large single-site high-risk cohort, and identify baseline demographic and clinical predictors beyond current APS/APSS criteria. METHOD: We prospectively studied 200 participants meeting criteria for both the SIPS APSS and DSM-5 APS. SIPS scores, demographics, family history of psychosis, DSM Axis-I diagnoses, schizotypy, and social and role functioning were assessed at baseline, with follow-up every 3 months for 2 years. RESULTS: The conversion rate was 30% (n = 60), or 37.7% excluding participants who were followed under 2 years. This rate was stable across time. Conversion time averaged 7.97 months for 60% who developed schizophrenia and 15.68 for other psychoses. Mean conversion age was 20.3 for males and 23.5 for females. Attenuated odd ideas and thought disorder appear to be the positive symptoms which best predict psychosis in a logistic regression. Total negative symptom score, Asian/Pacific Islander and Black/African-American race were also predictive. As no Axis-I diagnosis or schizotypy predicted conversion, the APS is supported as a distinct syndrome. In addition, cannabis use disorder did not increase risk of conversion to psychosis. CONCLUSIONS: NAPLS SIPS findings were replicated while controlling for clinical and demographic factors, strongly supporting the validity of the SIPS APSS and DSM-5 APS diagnosis.
Entities:
Keywords:
Attenuated psychosis; clinical high-risk for psychosis; first episode of psychosis; prodromal psychosis; schizotypy
Authors: Jennifer Abe-Kim; David T Takeuchi; Seunghye Hong; Nolan Zane; Stanley Sue; Michael S Spencer; Hoa Appel; Ethel Nicdao; Margarita Alegría Journal: Am J Public Health Date: 2006-11-30 Impact factor: 9.308
Authors: Rachel N Waford; Allison MacDonald; Katrina Goines; Derek M Novacek; Hanan D Trotman; Walker Elaine F; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Robert Heinssen; Daniel H Mathalon; Ming T Tsuang; Diana O Perkins; Larry J Seidman; Scott W Woods; Thomas H McGlashan Journal: Schizophr Res Date: 2015-05-18 Impact factor: 4.939
Authors: Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Eva Velthorst; Dorien H Nieman; Hiske E Becker; Reinaud van de Fliert; Peter M Dingemans; Rianne Klaassen; Lieuwe de Haan; Thérèse van Amelsvoort; Don H Linszen Journal: Schizophr Res Date: 2009-03-09 Impact factor: 4.939
Authors: Deborah J Walder; Carrie W Holtzman; Jean Addington; Kristin Cadenhead; Ming Tsuang; Barbara Cornblatt; Tyrone D Cannon; Thomas H McGlashan; Scott W Woods; Diana O Perkins; Larry J Seidman; Robert Heinssen; Elaine F Walker Journal: Schizophr Res Date: 2013-01-20 Impact factor: 4.939
Authors: Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Colleen A McFarlane; Mats Hallgren; Patrick D McGorry Journal: Schizophr Res Date: 2003-03-01 Impact factor: 4.939
Authors: Gregory P Strauss; Andrea Pelletier-Baldelli; Katherine Frost Visser; Elaine F Walker; Vijay A Mittal Journal: Schizophr Res Date: 2020-06-07 Impact factor: 4.939
Authors: Adam J Ciarleglio; Gary Brucato; Michael D Masucci; Rebecca Altschuler; Tiziano Colibazzi; Cheryl M Corcoran; Francesca M Crump; Guillermo Horga; Eugénie Lehembre-Shiah; Wei Leong; Scott A Schobel; Melanie M Wall; Lawrence H Yang; Jeffrey A Lieberman; Ragy R Girgis Journal: Psychol Med Date: 2018-06-28 Impact factor: 7.723
Authors: Pablo A Gaspar; Rolando I Castillo; Alejandro Maturana; María J Villar; Karen Ulloa; Gabriel González; Osvaldo Ibaceta; Andrea Ortiz; Sebastián Corral; Rocío Mayol; Valeria De Angel; María B Aburto; Antígona Martínez; Cheryl M Corcoran; Hernán Silva Journal: Early Interv Psychiatry Date: 2018-12-11 Impact factor: 2.732
Authors: Gary Brucato; Paul S Appelbaum; Jeffrey A Lieberman; Melanie M Wall; Tianshu Feng; Michael D Masucci; Rebecca Altschuler; Ragy R Girgis Journal: Neuropsychopharmacology Date: 2017-07-26 Impact factor: 7.853
Authors: Anthony W Zoghbi; Joel A Bernanke; Julia Gleichman; Michael D Masucci; Cheryl M Corcoran; Allegra Califano; Justin Segovia; Tiziano Colibazzi; Michael B First; Gary Brucato; Ragy R Girgis Journal: J Psychiatr Res Date: 2019-04-21 Impact factor: 4.791